0.7929
3.90%
-0.0322
After Hours:
.80
0.0071
+0.90%
Bolt Biotherapeutics Inc stock is currently priced at $0.7929, with a 24-hour trading volume of 594.64K.
It has seen a -3.90% decreased in the last 24 hours and a -28.57% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.846 pivot point. If it approaches the $0.7831 support level, significant changes may occur.
Previous Close:
$0.8251
Open:
$0.84
24h Volume:
594.64K
Market Cap:
$30.23M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-0.3887
EPS:
-2.04
Net Cash Flow:
$-69.73M
1W Performance:
-37.07%
1M Performance:
-28.57%
6M Performance:
-16.10%
1Y Performance:
-55.95%
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650 665 9295
Address
900 Chesapeake Drive, Redwood City
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-02-21 | Initiated | Guggenheim | Buy |
Mar-02-21 | Initiated | Morgan Stanley | Overweight |
Mar-02-21 | Initiated | SVB Leerink | Outperform |
Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Bio-Path Holdings, Inc. to Post Q2 2024 Earnings of ($2.06) Per Share, Roth Capital Forecasts (NASDAQ:BPTH) - Defense World
Defense World
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Bolt Biotherapeutics Inc (BOLT) Revenue 2024
BOLT reported a revenue (TTM) of $7.88 million for the quarter ending December 31, 2023, a +37.48% rise year-over-year.
Bolt Biotherapeutics Inc (BOLT) Net Income 2024
BOLT net income (TTM) was -$69.20 million for the quarter ending December 31, 2023, a +21.45% increase year-over-year.
Bolt Biotherapeutics Inc (BOLT) Cash Flow 2024
BOLT recorded a free cash flow (TTM) of -$69.73 million for the quarter ending December 31, 2023, a +11.12% increase year-over-year.
Bolt Biotherapeutics Inc (BOLT) Earnings per Share 2024
BOLT earnings per share (TTM) was -$1.83 for the quarter ending December 31, 2023, a +22.46% growth year-over-year.
About Bolt Biotherapeutics Inc
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Cap:
|
Volume (24h):